The estimated Net Worth of Mahady M Joseph is at least 22.7 千$ dollars as of 22 May 2020. Mr. Joseph owns over 2,069 units of Windtree Therapeutics stock worth over 22,738$ and over the last 13 years he sold WINT stock worth over 0$. In addition, he makes 0$ as Independent Director at Windtree Therapeutics.
Joseph has made over 1 trades of the Windtree Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 2,069 units of WINT stock worth 15,000$ on 22 May 2020.
The largest trade he's ever made was buying 2,069 units of Windtree Therapeutics stock on 22 May 2020 worth over 15,000$. On average, Joseph trades about 172 units every 0 days since 2012. As of 22 May 2020 he still owns at least 7,455 units of Windtree Therapeutics stock.
You can see the complete history of Mr. Joseph stock trades at the bottom of the page.
Joseph M. Mahady serves as Independent Director of the Company. He also serves as Chairman of the Board’s compensation committee and as a member of the audit committee. Mr. Mahady has extensive strategic and operational experience in the biopharmaceutical industry. He has broad international commercial experience, having served in a direct leadership role in more than 30 product launches, and has a successful record of developing profitable businesses based on transformational technologies in both the U.S. and international markets. Mr. Mahady held significant leadership positions during his 30-year career with Wyeth Corporation, including as President, Wyeth Pharmaceuticals from 2008 to 2009, and Senior Vice President, Wyeth Corporation from 2002 to 2009 with responsibility to direct the worldwide operations of that company’s $20 billion global pharmaceutical business. He retired from Wyeth Corporation in 2009. Since his retirement, Mr. Mahady served as Chairman of Lumara Health (formerly KV Pharmaceuticals) from 2013 to 2014, and as a member of the Boards of Directors of Albemarle from 2012 to 2015, EKR Therapeutics from 2011 to 2012 and Strongbridge Biopharma from 2012 to 2015. He currently serves on the Board of Advisors for Nevakar, Inc. Mr. Mahady received his B.S. degree in Pharmacy from St. John’s University College of Pharmacy and his M.B.A. in Pharmaceutical Studies from Fairleigh Dickinson University.
Joseph Mahady is 66, he's been the Independent Director of Windtree Therapeutics since 2013. There are 4 older and 10 younger executives at Windtree Therapeutics. The oldest executive at Windtree Therapeutics, Inc. is Mary Templeton, 73, who is the Senior Vice President, General Counsel and Corporate Secretary.
Mahady's mailing address filed with the SEC is 2600 KELLY ROAD, SUITE 100, WARRINGTON, PA, 18976.
Over the last 6 years, insiders at Windtree Therapeutics have traded over 1,982,541$ worth of Windtree Therapeutics stock and bought 6,849,036 units worth 20,224,921$ . The most active insiders traders include James Huang、Pharmaceutical Holdings Ltd...、Ii Investments Ltd Lph. On average, Windtree Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of 425,323$. The most recent stock trade was executed by Craig Fraser on 27 September 2023, trading 2,500 units of WINT stock currently worth 2,550$.
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Windtree Therapeutics executives and other stock owners filed with the SEC include: